#
May 20, 2020
Dr. Tapscott provides an update on his multi-year grant.
#
May 20, 2020
Dr. Marusak provides an update on progress so far.
#
May 19, 2020
Dyne to evaluate therapies targeting genetic cause of FSHD under agreement with international research organization University of Mons
#
May 13, 2020
Fulcrum amends their Phase 2b trial, ReDUX4, to extend the trial from 24 to 48 weeks, adds an interim analysis for subjects who underwent their 16-week biopsy as originally planned, and adds a 36-week biopsy for patients who cannot undergo their 16-week biopsy.